An Eli Lilly & Co. patent describes new relaxin receptor 1 (RXFP1; LGR7) agonists potentially useful for the treatment of diabetes, stroke, atherosclerosis and more.
Hepatocellular carcinoma is the most frequent form of primary liver cancer, and most patients are diagnosed when the disease is already advanced and therefore prognosis is poor despite available treatments. Understanding what contributes to the malignancy may help develop effective treatments.
Gastric cancer, which is the fifth most frequent cancer globally and the third most frequent cause of cancer-related deaths, can be managed relatively well with existing therapies. Advanced gastric cancer, in contrast, is more difficult to manage.
Acute myeloid leukemia (AML) is the most prevalent hematological malignancy. Despite advances in the field, about 60% of patients with AML do not survive >5 years. It is an urgent need to identify novel therapeutic targets for managing AML.
Persistent activation of the stimulator of interferon genes (STING), resulting from aberrant metabolism or mutations in STING1, can lead to inflammatory damage and autoimmune diseases. Therefore, inhibiting STING activity may offer therapeutic potential for treating these disorders.
Solve FSHD and Modalis Therapeutics Corp. have established a strategic collaboration to develop an innovative therapy for facioscapulohumeral muscular dystrophy (FSHD).
Researchers have investigated the role of the voltage-dependent potassium channel Kv1.3 in vivo in a murine model of ethanol-exposed alcohol-related liver disease (ALD).
Alys Pharmaceuticals Inc. has submitted a clinical trial application (CTA) to Germany’s Paul-Ehrlich-Institut (PEI) to initiate a phase I/Ib study of ALY-301 in healthy volunteers and patients with cold urticaria, a subtype of chronic inducible urticaria.
Myosin Therapeutics Inc. has obtained IND clearance by the FDA for MT-125. A phase I study will evaluate MT-125 in combination with standard-of-care radiation in patients with newly diagnosed IDH wild type, MGMT unmethylated glioblastoma.